Mabwell Bioscience-B

Innovative biotech focused on oncology & age-related diseases; core Nectin-4 ADC 9MW2821 in pivotal Phase III; 4 biosimilars launched

1) 56.8% for clinical development of 9MW2821 for multiple indications across phases;

2) 17.7% for R&D of other pipeline assets in oncology & age-related diseases with high clinical need;

3) 15.5% for commercialization;

4) 10.0% for working capital and general corporate purposes